206 related articles for article (PubMed ID: 19623660)
1. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.
Selvendiran K; Bratasz A; Kuppusamy ML; Tazi MF; Rivera BK; Kuppusamy P
Int J Cancer; 2009 Nov; 125(9):2198-204. PubMed ID: 19623660
[TBL] [Abstract][Full Text] [Related]
2. Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor.
McCann GA; Naidu S; Rath KS; Bid HK; Tierney BJ; Suarez A; Varadharaj S; Zhang J; Hideg K; Houghton P; Kuppusamy P; Cohn DE; Selvendiran K
Oncoscience; 2014; 1(3):216-28. PubMed ID: 25594014
[TBL] [Abstract][Full Text] [Related]
3. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
4. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
Han Z; Feng J; Hong Z; Chen L; Li W; Liao S; Wang X; Ji T; Wang S; Ma D; Chen G; Gao Q
Biochem Biophys Res Commun; 2013 May; 435(2):188-94. PubMed ID: 23665025
[TBL] [Abstract][Full Text] [Related]
5. Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions.
Selvendiran K; Kuppusamy ML; Ahmed S; Bratasz A; Meenakshisundaram G; Rivera BK; Khan M; Kuppusamy P
Cancer Biol Ther; 2010 Aug; 10(4):386-90. PubMed ID: 20562529
[TBL] [Abstract][Full Text] [Related]
6. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
7. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
Sheng WJ; Jiang H; Wu DL; Zheng JH
Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
[TBL] [Abstract][Full Text] [Related]
8. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
9. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
Dorayappan KDP; Wanner R; Wallbillich JJ; Saini U; Zingarelli R; Suarez AA; Cohn DE; Selvendiran K
Oncogene; 2018 Jul; 37(28):3806-3821. PubMed ID: 29636548
[TBL] [Abstract][Full Text] [Related]
11. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy.
Meng J; Liu K; Shao Y; Feng X; Ji Z; Chang B; Wang Y; Xu L; Yang G
Cell Death Dis; 2020 Feb; 11(2):137. PubMed ID: 32080166
[TBL] [Abstract][Full Text] [Related]
12. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
13. Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.
Tierney BJ; McCann GA; Naidu S; Rath KS; Saini U; Wanner R; Kuppusamy P; Suarez A; Goodfellow PJ; Cohn DE; Selvendiran K
Gynecol Oncol; 2014 Oct; 135(1):133-41. PubMed ID: 25038288
[TBL] [Abstract][Full Text] [Related]
14. CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract][Full Text] [Related]
15. Nuclear expression of pSTAT3
Marginean FE; Hellsten R; Krzyzanowska A; Bjartell A
Pathol Res Pract; 2022 Apr; 232():153811. PubMed ID: 35259550
[TBL] [Abstract][Full Text] [Related]
16. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
17. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
19. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs.
Butturini E; Carcereri de Prati A; Chiavegato G; Rigo A; Cavalieri E; Darra E; Mariotto S
Free Radic Biol Med; 2013 Dec; 65():1322-1330. PubMed ID: 24095958
[TBL] [Abstract][Full Text] [Related]
20.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
